Corium International (CORI) vs. Tetraphase Pharmaceuticals (TTPH) Head-To-Head Contrast
Corium International (NASDAQ: CORI) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
This table compares Corium International and Tetraphase Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Corium International has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Tetraphase Pharmaceuticals has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500.
Institutional & Insider Ownership
89.0% of Corium International shares are owned by institutional investors. Comparatively, 58.4% of Tetraphase Pharmaceuticals shares are owned by institutional investors. 30.8% of Corium International shares are owned by insiders. Comparatively, 5.5% of Tetraphase Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Corium International and Tetraphase Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corium International||$31.86 million||13.81||-$47.79 million||($1.58)||-7.71|
|Tetraphase Pharmaceuticals||$5.14 million||51.70||-$77.48 million||($2.86)||-1.80|
Corium International has higher revenue and earnings than Tetraphase Pharmaceuticals. Corium International is trading at a lower price-to-earnings ratio than Tetraphase Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings for Corium International and Tetraphase Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Corium International presently has a consensus target price of $13.00, suggesting a potential upside of 6.73%. Tetraphase Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 230.10%. Given Tetraphase Pharmaceuticals’ higher possible upside, analysts plainly believe Tetraphase Pharmaceuticals is more favorable than Corium International.
Corium International beats Tetraphase Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Corium International
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.